US · Healthcare

Zelira Therapeutics Limited (ZLDAF)

Biotechnology

Zelira Therapeutics Limited (ZLDAF) is listed on US in the Healthcare sector. Industry: Biotechnology. As of 2026-05-23, reported P/E ratio is 25.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Download on the App Store Get it on Google Play

Key metrics for ZLDAF

P/E ratio

25.00

Zelira Therapeutics Limited (ZLDAF) — FAQ

What is ZLDAF's P/E ratio?

The price-to-earnings (P/E) ratio for Zelira Therapeutics Limited (ZLDAF) is 25.00 (data as of 2026-05-23).

Does Zelira Therapeutics Limited pay a dividend?

Dividend yield is not available in the current snapshot for Zelira Therapeutics Limited (ZLDAF). Check the MyAverix Finance app for the latest dividend data.

What sector is Zelira Therapeutics Limited in?

Zelira Therapeutics Limited (ZLDAF) is classified in the Healthcare sector (Biotechnology industry).

What exchange is ZLDAF listed on?

ZLDAF is listed on US.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

Related Healthcare companies

Abbott Laboratories (ABT) AbbVie Inc. CDR (ABBV) Agilent Technologies Inc. (A1GI34) Aimed Bio (0009K0) Alnylam Pharmaceuticals, Inc. (A1LN34) Alvotech (ALVO) Amgen Inc (AMGN34) argenx SE (A1RG34)